Sleep quality improving agent and composition for improving sleep quality, daytime productivity improving agent and composition for improving daytime productivity, and concentration improving agent and composition for improving concentration

Abstract

To provide a sleep quality improver and a sleep quality-improving composition having excellent sleep quality-improving effect and high safety, to provide a daytime productivity improver and a daytime productivity-improving composition having excellent daytime productivity-improving effect and high safety, and to provide a concentration improver and a concentration improving-composition having excellent concentration-improving effect and high safety.SOLUTION: Provided are a sleep quality improver, a daytime productivity improver, or a concentration improver containing a compound represented by structural formula (1); and a sleep quality-improving composition containing the sleep quality improver, a daytime productivity-improving composition containing the daytime productivity improver, or a concentration improving composition containing the concentration improver.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a sleep quality improver and a composition for improving sleep quality, a daytime productivity improver and a composition for improving daytime productivity, and a concentration improver and a composition for improving concentration.

Background Art

[0002] Humans spend about one-third of their lives on "sleep," and sleep is considered the most important activity for humans. However, in modern society, due to disruptions in the rhythm of life, stress, lack of exercise, etc., there are many people who complain of symptoms of sleep deprivation and insomnia. In addition, the quality of sleep decreases with aging. Therefore, in the future, it is expected that the number of elderly people with a decreased quality of sleep will increase as the number of elderly people increases. The quality of sleep is affected by various factors such as physical factors, psychological factors, pharmacological factors, and environmental factors. Generally, it induces disorders such as poor sleep onset, middle-of-the-night awakenings, early awakenings, and non-restorative sleep. A decrease in the quality of sleep not only leads to serious diseases such as myocardial infarction and cerebral infarction, but also reduces productivity and concentration due to daytime sleepiness and fatigue, leading to serious accidents. Therefore, its improvement is an important issue.

[0003] So far, as a technique for improving the quality of sleep, a sleep quality improver containing delphinidin-3-rutinoside, cyanidin-3-rutinoside or a combination thereof as an active ingredient has been proposed (see, for example, Patent Document 1).

[0004] However, there is still a strong demand for a new material that has at least one of the effects of improving sleep quality, improving daytime productivity, and improving concentration, and has high safety, and thus can be widely used as a component of food and drink products, pharmaceuticals, research reagents, etc. At present, its prompt development is required.

Prior Art Documents

Patent Documents

[0005] [Patent Document 1] Japanese Patent Publication No. 2021-169441 [Overview of the project] [Problems that the invention aims to solve]

[0006] The present invention aims to solve the aforementioned problems of the conventional approach and achieve the following objectives. Specifically, the present invention aims to provide a sleep quality improving agent and a sleep quality improving composition that have excellent sleep quality improving effects and are highly safe. Furthermore, the present invention aims to provide a daytime productivity enhancer and a daytime productivity enhancer that have excellent daytime productivity-enhancing effects and are highly safe. Furthermore, the present invention aims to provide concentration-enhancing agents and concentration-enhancing compositions that have excellent concentration-enhancing effects and are highly safe. [Means for solving the problem]

[0007] In order to solve the aforementioned problems, the present inventors conducted extensive research and found that the compound represented by the following structural formula (1) has excellent effects in improving sleep quality, daytime productivity, and concentration, and is highly safe, making it useful for improving sleep quality, daytime productivity, and concentration. [ka]

[0008] The present invention is based on the inventors' aforementioned findings, and the means for solving the aforementioned problems are as follows: <1> This sleep quality improving agent is characterized by containing a compound represented by the following structural formula (1). [ka] <2> The aforementioned <1> This is a sleep quality improving composition characterized by containing the sleep quality improving agent described above. <3> This is a daytime productivity enhancer characterized by containing a compound represented by the following structural formula (1). [ka] <4> The aforementioned <3> This is a daytime productivity-enhancing composition characterized by containing the daytime productivity-enhancing agent described above. <5> This concentration-enhancing agent is characterized by containing a compound represented by the following structural formula (1). [ka] <6> The aforementioned <5> This is a concentration-enhancing composition characterized by containing the concentration-enhancing agent described above. [Effects of the Invention]

[0009] The sleep quality improving agent and sleep quality improving composition of the present invention can solve the aforementioned problems of the conventional methods, achieve the aforementioned objectives, and provide a sleep quality improving agent and sleep quality improving composition that have excellent sleep quality improving effects and are highly safe. The present invention provides a daytime productivity enhancer and daytime productivity enhancer that can solve the aforementioned problems of the past, achieve the aforementioned objectives, and provide a daytime productivity enhancer and daytime productivity enhancer that have excellent daytime productivity-enhancing effects and high safety. The concentration-enhancing agent and concentration-enhancing composition of the present invention can solve the aforementioned problems of the conventional methods, achieve the aforementioned objectives, and provide a concentration-enhancing agent and concentration-enhancing composition that have excellent concentration-enhancing effects and are highly safe. [Brief explanation of the drawing]

[0010] [Figure 1] Figure 1 shows the results of measuring the duration of wakefulness during the night in Test Example 1. [Figure 2A] Figure 2A shows the results of measuring the overall function of the autonomic nervous system in the group that consumed food containing the compound represented by structural formula (1) (test food) in Test Example 1. [Figure 2B] Figure 2B is a diagram showing the results of measuring the overall function of the autonomic nervous system in the group that ingested a food (control food) not containing the compound represented by Structural Formula (1) in Test Example 1.

Embodiments for Carrying Out the Invention

[0011] (Sleep Quality Improver, Daytime Productivity Improver, and Concentration Improver) The sleep quality improver of the present invention contains, as an active ingredient, a compound represented by the following Structural Formula (1), and further contains other components as necessary. The daytime productivity improver of the present invention contains, as an active ingredient, a compound represented by the following Structural Formula (1), and further contains other components as necessary. The concentration improver of the present invention contains, as an active ingredient, a compound represented by the following Structural Formula (1), and further contains other components as necessary.

Chemical Formula

[0012] In the present specification, improving the quality of sleep means making a state with poor sleep-wake (bad mood immediately after waking up) into a good state or approaching a good state, making a state without a sense of deep sleep during sleep-wake into a state with a sense of deep sleep during sleep-wake or approaching such a state, and shortening the middle awakening time when waking up several times at night.

[0013] In the present specification, improving daytime productivity means enhancing the overall daytime performance, making a state where the daytime concentration cannot be sustained into a state where it can be sustained for a longer time or into a state where it can be sustained for an even longer time, and increasing the overall function of the autonomic nervous system during the day or enhancing the autonomic nerve activity.

[0014] In the present specification, improving concentration means making a state where concentration cannot be sustained into a state where it can be sustained for a longer time or into a state where it can be sustained for an even longer time.

[0015] The compound represented by the structural formula (1) has excellent effects in at least one of the following: improving sleep quality, improving daytime productivity, and improving concentration. It is previously unknown that the compound is useful as a sleep quality improver, a daytime productivity improver, or a concentration improver, and this is a new finding by the present inventors.

[0016] <Compound represented by structural formula (1)> The compound represented by the following structural formula (1) is named 3-(4-hydroxy-3-methoxyphenyl)propionic acid (hereinafter sometimes referred to as "HMPA"). [ka]

[0017] The compound represented by the structural formula (1) is a known compound, and commercially available products may be used, or compounds extracted from plants may be used.

[0018] There are no particular restrictions on the amount of the compound represented by structural formula (1) in the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent of the present invention, and it can be appropriately selected depending on the purpose. The sleep quality improving agent, the daytime productivity improving agent, and the concentration improving agent may consist solely of the compound represented by the structural formula (1).

[0019] <Other ingredients> The aforementioned other components are not particularly limited as long as they do not impair the effects of the present invention, and can be appropriately selected depending on the form in which the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent are used. Examples include excipients, moisture-proofing agents, preservatives, fortifiers, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, seasonings, colorants, fragrances, whitening agents, moisturizers, oily components, UV absorbers, surfactants, thickeners, alcohols, powder components, colorants, aqueous components, water, skin nutrients, etc. These may be used individually or in combination of two or more.

[0020] There are no particular restrictions on the amount of the aforementioned other components in the sleep quality improving agent, daytime productivity improving agent, and concentration improving agent, and they can be appropriately selected according to the purpose.

[0021] <Application> There are no particular restrictions on the use of the aforementioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent, and they can be appropriately selected according to the purpose. Examples include pharmaceuticals, quasi-drugs, and food and beverages. The aforementioned sleep quality improving agent has excellent sleep quality improving effects and is highly safe, so it can be suitably used, for example, as an active ingredient in the sleep quality improving composition described later. The aforementioned daytime productivity enhancer has excellent daytime productivity-enhancing effects and high safety, and can therefore be suitably used, for example, as an active ingredient in daytime productivity-enhancing compositions described later. The aforementioned concentration-enhancing agent has excellent concentration-enhancing effects and high safety, and can therefore be suitably used, for example, as an active ingredient in a concentration-enhancing composition described later.

[0022] The sleep quality improving agent, daytime productivity improving agent, and concentration improving agent of the present invention are suitably applied to humans, but can also be applied to animals other than humans (e.g., mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their effects are achieved.

[0023] There are no particular restrictions on the use of the aforementioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent; they can be appropriately selected according to the purpose, for example, by oral administration, parenteral administration, or topical application.

[0024] The site of use, method of use, and dosage form of the aforementioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent can be appropriately selected according to their intended use.

[0025] The aforementioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent can be formulated into any dosage form such as powder, granules, tablets, or liquid, according to conventional methods, using pharmaceutically acceptable carriers such as dextrin and cyclodextrin, or other optional excipients. In this case, excipients such as excipients, binders, disintegrants, lubricants, stabilizers, and flavoring / odorizing agents can be used. The aforementioned sleep quality improving agent, daytime productivity improving agent, and concentration improving agent can be used in combination with other compositions (for example, the sleep quality improving composition, daytime productivity improving composition, concentration improving composition, etc. described later), as well as in parenteral administration agents such as injections, intravenous drips, and suppositories, or in ointments, eye drops, topical solutions, and patches.

[0026] There are no particular restrictions on the dosage, duration, or interval of use of the aforementioned sleep quality improving agents, daytime productivity improving agents, and concentration improving agents; they can be appropriately selected according to the purpose.

[0027] Furthermore, the sleep quality improving agent of the present invention can be used as a reagent for research on the mechanism of action of sleep quality improvement, the daytime productivity improving agent of the present invention for daytime productivity improvement, and the concentration improving agent of the present invention for concentration improvement.

[0028] (Compositions for improving sleep quality, compositions for improving daytime productivity, and compositions for improving concentration) The sleep quality improving composition of the present invention comprises the sleep quality improving agent of the present invention, and further comprises other components as needed. The daytime productivity-enhancing composition of the present invention comprises the daytime productivity-enhancing agent of the present invention, and further comprises other components as needed. The concentration-enhancing composition of the present invention comprises the concentration-enhancing agent of the present invention, and further comprises other components as necessary.

[0029] <Sleep quality improvers, daytime productivity improvers, and concentration improvers> The aforementioned sleep quality improving agent is the sleep quality improving agent of the present invention described above. The aforementioned daytime productivity enhancer is the daytime productivity enhancer of the present invention described above. The aforementioned concentration-enhancing agent is the concentration-enhancing agent of the present invention described above.

[0030] There are no particular restrictions on the content of the sleep quality improving agent in the sleep quality improving composition, and it can be appropriately adjusted depending on the form of the sleep quality improving composition, but it is preferably 0.0001% to 20% by mass, and more preferably 0.0001% to 10% by mass, when converted to the amount of the compound represented by structural formula (1). The sleep quality improving composition may consist only of the sleep quality improving agent.

[0031] There are no particular restrictions on the content of the daytime productivity improving agent in the daytime productivity improving composition, and it can be appropriately adjusted depending on the form of the daytime productivity improving composition, but it is preferably 0.0001% to 20% by mass, and more preferably 0.0001% to 10% by mass, when converted to the amount of the compound represented by structural formula (1). The daytime productivity improving composition may consist only of the daytime productivity improving agent.

[0032] There are no particular restrictions on the content of the concentration-enhancing agent in the concentration-enhancing composition, and it can be appropriately adjusted depending on the form of the concentration-enhancing composition, but it is preferably 0.0001% to 20% by mass, and more preferably 0.0001% to 10% by mass, when converted to the amount of the compound represented by structural formula (1). The concentration-enhancing composition may consist only of the concentration-enhancing agent.

[0033] <Other ingredients> Other components in the aforementioned sleep quality improving composition, daytime productivity improving composition, and concentration improving composition are not particularly limited and can be appropriately selected depending on the form of use of the sleep quality improving composition, daytime productivity improving composition, and concentration improving composition. Examples include those similar to the other components described in the sections on sleep quality improving agents, daytime productivity improving agents, and concentration improving agents. These may be used individually or in combination of two or more.

[0034] There are no particular restrictions on the content of the aforementioned other components in the sleep quality improvement composition, the daytime productivity improvement composition, and the concentration improvement composition, and they can be appropriately selected according to the purpose.

[0035] <Nature> There are no particular limitations on the form of the composition for improving sleep quality, the composition for improving daytime productivity, and the composition for improving concentration, and they can be appropriately selected according to the purpose. Examples include pharmaceuticals, quasi-drugs, and food and beverages. The sleep quality improving composition, daytime productivity improving composition, and concentration improving composition of the present invention can be used on a daily basis, and the compound represented by the structural formula (1) above, which is the active ingredient, can exert various physiologically active effects, including sleep quality improvement, daytime productivity improvement, and concentration improvement, with great effectiveness.

[0036] The sleep quality improvement composition, daytime productivity improvement composition, and concentration improvement composition of the present invention are suitably applied to humans, but can also be applied to animals other than humans (e.g., mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective effects are achieved.

[0037] There are no particular limitations on the use of the sleep quality improvement composition, daytime productivity improvement composition, and concentration improvement composition of the present invention, and the method can be appropriately selected according to the purpose. For example, methods of use include oral administration, parenteral administration, and topical administration, but oral administration is preferred.

[0038] Examples of the oral compositions mentioned above include the oral preparations and foods and beverages described above. Here, "food and beverages" refers to substances that pose little risk to human health and are consumed orally or through the gastrointestinal tract in normal social life, and is not limited to administrative classifications such as food, pharmaceuticals, or quasi-drugs. Therefore, "food and beverages" broadly includes foods and beverages that constitute general foods, health foods (functional foods and beverages), health functional foods (foods for specified health uses, nutrient function foods, foods with functional claims), quasi-drugs, pharmaceuticals, etc., that are ingested orally.

[0039] There are no particular restrictions on the type of oral composition, and it can be appropriately selected according to the purpose. Examples include: beverages such as tea beverages, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, alcoholic beverages, coffee beverages, coffee-flavored soft drinks, etc. (including concentrated stock and powders for adjusting these beverages); frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, vermicelli, gyoza wrappers, shumai wrappers, Chinese noodles, and instant noodles; confectionery such as candy, gum, chocolate, tablets, snacks, biscuits, jelly, jam, cream, baked goods, and bread; marine products such as crab, salmon, clams, tuna, sardines, shrimp, bonito, mackerel, whale, oysters, saury, squid, ark clams, scallops, abalone, sea urchin, salmon roe, and tokobushi; kamaboko, ha Examples of products include processed seafood and livestock products such as sausages; dairy products such as processed milk and fermented milk; oils and processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings; seasonings such as sauces and dips; retort pouch foods such as curry, stew, oyakodon, porridge, rice gruel, chukadon, katsudon, tempuradon, unadon, hayashi rice, oden, mapo tofu, gyudon, meat sauce, egg soup, omurice, gyoza, shumai, hamburgers, and meatballs; prepared foods such as salads and pickles; health, beauty, and nutritional supplements in various forms; pharmaceuticals and quasi-drugs such as tablets, powders, capsules, granules, extracts, syrups, drinks, lozenges, and mouthwashes; and oral fresheners and toothpastes used in the mouth, such as mouth fresheners and bad breath preventatives.

[0040] There are no particular limitations on the method for manufacturing the sleep quality improving composition, the daytime productivity improving composition, and the concentration improving composition, and the method can be appropriately selected depending on the form in which the sleep quality improving composition, the daytime productivity improving composition, and the concentration improving composition are used.

[0041] There are no particular restrictions on the amount, duration, or interval of use of the aforementioned sleep quality improvement composition, daytime productivity improvement composition, and concentration improvement composition, and they can be appropriately selected according to the purpose.

[0042] As described above, the sleep quality improving agent and sleep quality improving composition of the present invention have excellent sleep quality improving effects. Therefore, the present invention also relates to a method for improving sleep quality, characterized by administering to an individual at least one selected from the group consisting of sleep quality improving agents and sleep quality improving compositions.

[0043] As described above, the daytime productivity enhancer and daytime productivity enhancer of the present invention have excellent daytime productivity enhancing effects. Therefore, the present invention also relates to a method for improving daytime productivity, characterized by administering to an individual at least one selected from the group consisting of daytime productivity improving agents and daytime productivity improving compositions.

[0044] As described above, the concentration-enhancing agent and concentration-enhancing composition of the present invention have excellent concentration-enhancing effects. Therefore, the present invention also relates to a method for improving concentration, characterized by administering to an individual at least one selected from the group consisting of the concentration-enhancing agent and the concentration-enhancing composition. [Examples]

[0045] The following describes test examples and formulation examples of the present invention, but the present invention is not limited in any way to these test examples and formulation examples.

[0046] (Test Example 1) Clinical trials of the compound represented by the structural formula (1) were conducted as follows. · test Randomized, double-blind, placebo-controlled comparative trial · subject 30 healthy adult men and women aged 40 to under 65 (15 people per group x 2 groups) · Method Actibody TM Participants consumed either RB 100mg capsules (manufactured by Maruzen Pharmaceutical Co., Ltd., ingesting 23mg / day of the compound represented by the above structural formula (1)) (hereinafter sometimes referred to as the "test food intake group") or a placebo (hereinafter sometimes referred to as the "control food intake group") for four weeks. • Evaluation items (A) Questionnaire survey (pre-intake examination, 4-week post-intake examination) (B) Wristwatch-type activity tracker (Silmee TM Evaluation of sleep quality (time spent awake during the night) using W22) (during the intake period) Evaluation was based on the average value over one week at the start of intake and at the fourth week of intake. (C) Watch-type activity tracker (Silmee) TM Autonomic nervous system activity assessment using W22) (during the intake period) Evaluation was based on the average value over one week at the start of intake and at the fourth week of intake.

[0047] <Result> [(A) Questionnaire Survey - 1] Participants were asked to rate their overall performance on their workdays over the past four weeks on an 11-point scale from 0 to 10, with 0 being the worst and 10 being the best. As a result, in the group that consumed the test food, the score was "6.9±0.4" ("mean ± standard error," the same applies below) in the pre-intake test and "7.3±0.4" in the 4-week test. On the other hand, in the group that consumed the control food, the score was "6.5±0.4" in the pre-intake test and "6.6±0.3" in the 4-week test. In the group that consumed the test food, a significant increase in evaluation scores was confirmed in the 4-week test compared to the group that consumed the control food (Mann-Whitney U test).

[0048] [(A) Questionnaire Survey - 2] Participants were asked to rate whether they "cannot maintain concentration" on a 7-point scale from 1 to 7, with 7 being the worst rating (applies) and 1 being the best rating (does not apply). As a result, in the group that consumed the test food, the score was "2.6±0.3" ("mean ± standard error," the same applies below) in the pre-intake test and "2.3±0.4" in the 4-week test. On the other hand, in the group that consumed the control food, the score was "2.6±0.3" in the pre-intake test and "3.1±0.4" in the 4-week test. In the group that consumed the test food, a significant decrease in the evaluation score from the pre-intake test was confirmed in the 4-week test compared to the control food group (Mann-Whitney U test).

[0049] [(A) Questionnaire Survey - 3] Participants were asked to rate whether they felt "bad upon waking" (how they felt immediately after waking up) on a 7-point scale from 1 to 7, with 7 being the worst rating (feeling bad) and 1 being the best rating (not feeling bad). As a result, in the group that consumed the test food, the score was "3.0±0.4" ("mean ± standard error," the same applies below) in the pre-intake test and "2.5±0.2" in the 4-week test. On the other hand, in the group that consumed the control food, the score was "2.1±0.4" in the pre-intake test and "2.7±0.3" in the 4-week test. In the group that consumed the test food, a significant decrease in the evaluation score from the pre-intake test was confirmed in the 4-week test compared to the control food group (Mann-Whitney U test).

[0050] [(A) Questionnaire Survey - 4] Participants were asked to rate whether they felt they did not feel well-rested upon waking, using a 7-point scale from 1 to 7, with 7 being the worst rating (feeling well) and 1 being the best rating (not feeling well). As a result, in the group that consumed the test food, the score was "3.1±0.4" ("mean ± standard error," the same applies below) in the pre-intake test and "2.8±0.3" in the 4-week test. On the other hand, in the group that consumed the control food, the score was "3.4±0.4" in the pre-intake test and "3.6±0.3" in the 4-week test. In the group that consumed the test food, a significant decrease in evaluation scores was confirmed in the 4-week test compared to the group that consumed the control food (Mann-Whitney U test).

[0051] [(B) Evaluation of sleep quality (time spent awake during the night) using a wrist-worn activity tracker] Figure 1 shows the results of measuring the amount of time spent awake during the night, which is related to sleep quality, using a wrist-worn activity tracker. In Figure 1, the vertical axis represents the change in the duration of middle-of-the-night awakenings from the start of intake at the fourth week of intake, and the horizontal axis represents each food intake group. Furthermore, "□" represents the results for the test food intake group, and "■" represents the results for the control food intake group. As shown in Figure 1, at the fourth week of intake, it was confirmed that the group consuming the test food had shorter periods of wakefulness during the night compared to the group consuming the control food.

[0052] [(C) Evaluation of autonomic nervous system activity using a wristwatch-type activity tracker] The results of measuring the overall function of the autonomic nervous system using a wristwatch-type activity tracker are shown in Figure 2A (test food intake group) and Figure 2B (control food intake group). The overall function of the autonomic nervous system was assessed by performing frequency analysis based on data acquired from the accelerometer of a wristwatch-type activity tracker. The sum of the power values ​​of the low-frequency (LF) and high-frequency (HF) components of the spectrum (total power; an indicator of the overall function of the autonomic nervous system) was calculated. In Figures 2A and 2B, the vertical axis represents the total power (measured value) of the overall autonomic nervous system function, and the horizontal axis represents the time period (0-6: 0 to 6am, 6-12: 6am to 12pm, 12-18: 12pm to 6pm, 18-24: 18pm to 12am). "●" indicates the result at the start of intake, and "■" indicates the result after 4 weeks of intake. As shown in Figures 2A and 2B, in the group that consumed the test food, overall autonomic nervous system activity during the daytime (6:00-18:00) was higher at 4 weeks of consumption compared to the start of consumption. On the other hand, in the group that consumed the control food, no difference was observed in autonomic nervous system activity during the daytime (6:00-18:00) between the start of consumption and 4 weeks of consumption.

[0053] (Combination example 1) Tablets having the following composition were manufactured by conventional methods. • 5.0 mg of the compound represented by the above structural formula (1) Dolomite 83.4mg (Contains 20% calcium and 10% magnesium) Casein phosphopeptide 16.7 mg • Vitamin C 33.4mg • Maltitol 136.8mg • Collagen 12.7mg • Sucrose fatty acid ester 12.0 mg

[0054] (Combination example 2) An oral liquid formulation having the following composition was manufactured by a conventional method. <Composition per ampoule (100 mL)> • Compound represented by the above structural formula (1): 0.3% by mass • Sorbitol 12.0% by mass • Sodium benzoate 0.1% by mass · Fragrance 1.0% by mass • Calcium sulfate 0.5% by mass · Purified water remainder

[0055] (Combination example 3) A coffee beverage having the following composition was manufactured using conventional methods. • Compound represented by the above structural formula (1): 0.1% by mass • Coffee extract (L (brightness) = 20, Brix = 3) 40.0% by mass • Maltitol 2.0% by mass · Appropriate amount of fragrance · Water remainder

[0056] (Combination example 4) Capsules having the following composition were manufactured by conventional methods. No. 1 hard gelatin capsules were used as the capsules. <Composition per capsule (200mg tablet)> • 30.0 mg of the compound represented by the above structural formula (1) • Corn starch 70.0 mg · Lactose 80.0mg • Calcium lactate 10.0 mg • Hydroxypropylcellulose (HPC-L) 10.0 mg

Claims

1. A sleep quality improving agent comprising a compound represented by the following structural formula (1), A sleep quality improving agent characterized in that the improvement in sleep quality is at least one of the following selected from the group consisting of improving or bringing closer to improving poor waking conditions, improving or bringing closer to improving conditions where there is no feeling of deep sleep upon waking, and shortening the time spent awake during the night. 【Chemistry 1】

2. A composition for improving sleep quality, comprising the sleep quality improving agent described in claim 1, A sleep quality improving composition characterized in that the improvement in sleep quality is at least one selected from the group consisting of improving or approaching the condition of having poor sleep quality upon waking, improving or approaching the condition of having a feeling of deep sleep upon waking, and shortening the time spent awake during the night.

3. A daytime productivity enhancer comprising a compound represented by the following structural formula (1), A daytime productivity enhancer characterized in that the daytime productivity improvement is at least one selected from the group consisting of improving overall daytime performance and changing a state in which daytime concentration cannot be sustained to a state in which concentration can be sustained for a long time or to a state in which concentration can be sustained for a longer period of time. 【Chemistry 2】

4. A daytime productivity improving composition comprising the daytime productivity improving agent described in claim 3, A composition for improving daytime productivity, characterized in that the improvement of daytime productivity is at least one selected from the group consisting of improving overall performance during the day and changing a state in which concentration cannot be sustained during the day to a state in which concentration can be sustained for a long time or a state in which concentration can be sustained for a longer period of time.

5. A concentration-enhancing agent comprising a compound represented by the following structural formula (1), A concentration-enhancing agent characterized by improving concentration by changing a state in which concentration cannot be sustained to a state in which concentration can be sustained for a long period of time or a state in which concentration can be sustained for a longer period of time. 【Transformation 3】

6. A composition for improving concentration, comprising the concentration-enhancing agent described in claim 5, A composition for improving concentration, characterized in that it transforms a state in which concentration cannot be sustained into a state in which concentration can be sustained for a long period of time or a state in which concentration can be sustained for a longer period of time.

Images